Personalized, tumor-informed, circulating tumor DNA assay for detecting minimal residual disease in non-small cell lung cancer patients receiving curative treatments.
Youjin OhSung Mi YoonJeeyeon LeeJoo Hee ParkSoowon LeeTimothy HongLiam Il-Young ChungSumedha SudhamanTimothy RiddellCharuta C PalsuledesaiMichael KrainockMinetta C LiuYoung Kwang ChaePublished in: Thoracic cancer (2024)
Our real-world data indicate that longitudinal, personalized, tumor-informed ctDNA monitoring is a valuable tool in patients with NSCLC receiving curative treatment to identify patients at high risk for recurrence.
Keyphrases
- circulating tumor
- cell free
- circulating tumor cells
- prognostic factors
- end stage renal disease
- ejection fraction
- newly diagnosed
- small cell lung cancer
- chronic kidney disease
- rectal cancer
- high throughput
- cross sectional
- advanced non small cell lung cancer
- big data
- patient reported outcomes
- deep learning
- data analysis
- brain metastases